Mr. Chris Koch reports

LED MEDICAL DIAGNOSTICS' VELSCOPE(R) VX RECEIVES REGULATORY APPROVAL FOR DISTRIBUTION IN CHINA

LED Medical Diagnostics Inc. and its subsidiary LED Dental have received regulatory approval for the distribution of the VELscope Vx enhanced oral assessment system in China, opening up a large new market for the award-winning adjunctive screening device. Geneformation Technology, a distributor of laboratory equipment and consumables with offices in China, Hong Kong and the United States, has worked closely with the company to obtain regulatory approval for the VELscope Vx from the China Food and Drug Administration. As of Aug. 6, 2015, the VELscope Vx enhanced oral assessment system has been approved for sale in China as a medical apparatus, Category I, under approval No. 20151176.

"China has the largest population globally, so this is a significant milestone for our company," said Dr. David Morgan, chief technology officer of LED Dental. "Ongoing reform of the Chinese dental care system, coupled with a rise in per-capita disposable income and an increased awareness of health, is bolstering accelerated growth of China's oral health care industry. The result is the emergence of a large number of small private new clinics that are taking advantage of relaxed government regulations for private health care centres. Over 50,000 of these are estimated to be in operation to date."

"The Chinese dental market is a significant opportunity for global expansion of the VELscope Vx system," remarked Wayne Rees, vice-president of VELscope imaging for LED Dental. "Our partnership with Geneformation Technology Inc. will provide an experienced distribution channel to the influential university and hospital markets in both China and Hong Kong, which provide the majority of dental services in China through thousands of state-run dental hospitals."

The VELscope Vx enhanced oral assessment system is the dental industry's leading adjunctive screening device for the early visualization of a range of oral mucosal abnormalities, including oral cancer, precancer, infections and trauma. To date, more than 25 million VELscope Vx exams have been performed by over 15,000 dentists in 23 countries.

We seek Safe Harbor.